Genmab AS ADR (GMAB)
Genmab A/S ADR is a NASDAQ-listed depositary receipt representing common stock of Genmab A/S, a biotechnology company based in Copenhagen, Denmark. The company develops antibody-based medicines and product candidates for cancer and other serious diseases. Its marketed products include EPKINLY and TEPKINLY for certain relapsed or refractory B-cell lymphomas, and Tivdak for recurrent or metastatic cervical cancer after chemotherapy. Genmab is also advancing a pipeline that includes Epcoritamab, tisotumab vedotin, Acasunlimab, Rinatabart Sesutecan, GEN1059, GEN1055, GEN1057, and GEN1286 across multiple oncology indications, as well as programs such as Amlenetug, Inclacumab, and Mim8 in other disease areas. In addition, it has collaborations with several pharmaceutical and biotechnology companies, including AbbVie, Pfizer, BioNTech, Johnson & Johnson, Bristol Myers Squibb, Lundbeck, Amgen, Novo Nordisk, and argenx.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GMAB
|
$50.40
|
-1.9% Downside
|
Fair
|
$65.10
|
26.7% Upside
|
Undervalued
|
Great
|
0.0%
|
February 24, 2027
|
44.1x
|
5.1x
|
7.5x
|
32.182 B
|
35.411 B
|
13.6%
|
93.1%
|
14.1
|
116.7%
|